Combination TherapyApproved for: NSCLCPD-L1 Pembrolizumab (Keytruda) approved Combination Therapy for non-small cell lung cancer (NSCLC) with the biomarker PD-L1. It is used: Alone as first-line treatment in patients whose cancer has the PD-L1 protein and does not have a
...
Combination TherapyApproved for: NSCLC Non-small cell lung cancer. It is used: With carboplatin and either paclitaxel or paclitaxel albumin-stabilized nanoparticle formulation as first-line treatment for metastatic squamous disease. Related Research News Keytruda Meets Trial Goals for Non-Small Cell Lung
...
ImmunotherapyApproved for: SCLC Pembrolizumab (Keytruda) is a FDA-approved treatment for small cell lung cancer (SCLC) that has metastasized. It is used in patients whose disease got worse during or after treatment with platinum chemotherapy and at least one other
...
The FDA granted approval to pembrolizumab (Keytruda, Merck), an anti-PD-1 checkpoint immunotherapy, for first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) that is PD-L1-positive and is not amenable to surgery or chemo-radiation treatment. Search for…
In the phase 3 KEYNOTE-671 trial evaluating Keytruda (pembrolizumab) as preoperative treatment (a regimen given before and after surgier) in patients with resectable stage 2, 3a or 3b non-small cell lung cancer has met one of its primary endpoints…